Study of efficacy of aflibercept in neovascular age-related macular degeneration (wAMD) with non-responder of ranibizumab
- Conditions
- Age-related macular degeneration
- Registration Number
- JPRN-UMIN000010577
- Lead Sponsor
- agoya City University Graduate School of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Not provided
1) Greatest Linear Dimension (GLD) of the total lesion area <12 Macular Photocoagulation Study Disc Areas 2) Prior treatment with photodynamic therapy (PDT) within the past 3 months or more than 4 prior PDT treatment 3) Presence of RPE tears, or subretinal hemorrhage, scar or macular fibrosis (>50% lesion area area) 4) Prior treatment with aflibercept 5) Prior treatment with triamcinolone within 6 months 6) Prior treatment with dexamethasone within 30 days 7) Intraocular surgery within 6 months, vitrectomy surgery, submacular surgery, or other surgical intervention for AMD 8) Active intraocular inflammation 9) Hypersensitivity or allergy to fluorescein or indocyanine green, clinically significant drug allergy or known hypersensitivity to therapeutic or diagnostic protein products
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Macula fluid on OCT at month 3
- Secondary Outcome Measures
Name Time Method Change of BCVA, central macular thickness